Genzyme CorporateSearchGenzyme Websites
MPSI Disease Treatment Information for Patients and FamiliesMPSI Disease Treatment Information for Health Care Providers
MPSI
Health Care Professionals
Disease Overview
Genetics and MPS I
Severe and Attenuated
Symptoms & Symptom Management
Disease Progression
The MPS Family of Diseases
Lysosomal Storage Disorders
Diagnosing MPS I
Treatment Options
The MPS I Registry
Resources and Support

Cardiovascular System

General Physical Appearance
Nervous System

Skeletal System

Respiratory System

Auditory System

Cardiovascular System

Ocular System

Gastrointestinal System

Clinical complications related to heart disease occur in all individuals with MPS I, particularly during the later stages of MPS I disease.[2] Evidence of cardiovascular involvement by echocardiography can be demonstrated much earlier than that derived from clinical observations.

Mildly affected people with the attenuated form of MPS I may develop problems with the aortic or mitral valves. Storage of GAGs within and around the valve leaflets results in their thickening and stiffening which can lead to progressive mitral and aortic regurgitation (Image 1).[1] The valvular disease does not usually lead to hemodynamic effects until the later stages of disease. People with attenuated disease who have moderate to severe symptoms (Hurler-Scheie syndrome) can also develop valve disease and may need mitral or aortic valve replacement in their teens and twenties.[2]

Pathological specimen showing thickened and deformed valvular leaves
Image 1
- Pathological specimen showing thickened and deformed valvular leaves

Courtesy of J.E. Wraith, MD

In severe patients, as GAG storage continues in the heart, cardiomyopathy may trigger sudden death related to arrhythmia, coronary artery disease and cardiovascular collapse. A small subset of severe MPS I patients exhibit early onset of fatal endocardiofibroelastosis, presenting in the first year of life. Mitral regurgitation is the more common valvular disease in severe MPS I.[1]

Valve replacement surgery may be considered early in association with a general assessment of a patient’s clinical condition. Cardiac evaluation through serial monitoring of ventricular size, wall thickness and function at regular intervals (at least annually) with echocardiography is useful in the treatment of patients. Bacterial endocarditis prophylaxis may be advised for MPS I patients with cardiac abnormalities.[2]

Next: Ocular System

References:

1. Wippermann CF, Beck M, Schranz D, Huth R, Michel-Behnke I, Jungst BK. Mitral and aortic regurgitation in 84 patients with mucopolysaccharidoses. Eur J Pediatr 1995;154(2):98-101.

2. Neufeld, E.F., and Muenzer, J. (2001) The mucopolysaccharidoses. In: The Metabolic and Molecular Bases of Inherited Disease. Scriver, C.R., Beaudet, A.L., Sly, W.S., Valle, D., Childs, B., Kinzler, K.W., and Vogelstein, B. (eds.). 8th edition, Vol. III. McGraw- Hill, Medical Publishing Division, p. 3421.

Did you know...
Genetic counselors are health professionals who are trained to help families understand genetic disorders such as MPS I disease. A genetic counselor can help you determine if you are a carrier of a gene defect that causes MPS I and can provide valuable information and support for family planning. Visit the European Society of Human Genetics or the National Society of Genetic Counselors to learn more.
Watch Video
Meet Denise, a 40-year-old woman with MPS I who enjoys her life to the fullest.
Watch the Video
Genzyme Corporation
500 Kendall Street
Cambridge, MA 02142 USA
Phone: 617-768-9000 or
800-745-4447
Contact Genzyme